SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

by Yejin Yang on the 20 February 2019

Cases of necrotising fasciitis of the genitalia or perineum, also known as Fournier's gangrene, have been reported in patients with type 2 diabetes taking sodium glucose co-transporter 2 (SGLT2) inhibitors, the MHRA has said.

Fournier's gangrene is a urological emergency that requires prompt medical treatment. | iStock.com/Jomkwan
Fournier's gangrene is a urological emergency that requires prompt medical treatment. | iStock.com/Jomkwan

Fournier's gangrene is a rare but potentially life-threatening bacterial infection of the tissue underlying the skin surrounding the perineal muscles, nerves, fat, and blood vessels.

Further information

View SGLT2 inhibitor drug records MHRA Drug Safety Update MIMS Diabetes Clinic

Prescribers should advise patients taking SGLT2 inhibitors to seek medical attention immediately if they experience symptoms such as severe pain, tenderness, erythema or swelling in the genital or perineal area accompanied by fever or malaise.

If Fournier’s gangrene is suspected, the SGLT2 inhibitor should be stopped and appropriate treatments should be started immediately.

The MHRA says it has received 6 Yellow Card reports of UK cases of Fournier’s gangrene in patients on SGLT2 inhibitors up to January 2019. Of these cases, 4 were in men and 2 were in women.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter